Infant and Parent Shared Book Reading

January 14, 2025 updated by: University of Florida

Parent-infant Learning Dynamics During Early Shared Book Reading

This work is guided by two specific aims and is expected to result in a better understanding of the effectiveness of shared book reading as a tool for supporting parent-infant interactions and infant learning across the first year of life. This work determined the extent to which books with individually-named characters (e.g., "Boris", "Fiona") increases parent-infant joint attention and infant selective attention relative to books with generic labels (e.g., "Bear", "Bear") or no labels and whether attention differs by age. During infant-parent shared book reading joint attention was measured using dual eye-tracking. Infants and parents then returned to the lab the next day and infant selective attention and infant-parent neural synchrony was measured using EEG.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Shared book reading has been found to have broad developmental benefits for language, socio-emotional and cognitive development. However, the effects of shared book reading on infant development are not well understood. Although healthcare professionals and educators ask parents to read books to their infants early and often, the book reading experience itself has never been systematically investigated in infancy. This work is guided by two specific aims and is expected to result in a better understanding of the effectiveness of shared book reading as a tool for supporting parent-infant interactions and infant learning across the first year of life. The primary aim of the proposed work is to determine the extent to which books with individually-named characters (e.g., "Boris", "Fiona") increases parent-infant joint attention and infant selective attention relative to books with generic labels (e.g., "Bear", "Bear") or no labels and whether attention differs by age. To address the aim of this project, a cross-sectional sample of 6-, 9-, and 12-month old infants and their parents came to the laboratory and read a book that includes three distinct character labeling conditions (individual names, generic category labels, no label). During infant-parent shared book reading joint attention was measured using dual eye-tracking. Infants and parents then returned to the lab the next day and infant selective attention and infant-parent neural synchrony was measured using EEG frequency tagging while infants and their parent viewed familiar characters across labeling conditions as well as unfamiliar characters. This project determined the extent to which parent-infant shared book reading impacted infant attention, parent-infant joint attention, EEG power, and parent-infant EEG synchrony.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
146

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Lisa Scott, PhD
  • Phone Number: 352-273-2125
  • Email: lscott@ufl.edu

Study Contact Backup

  • Name: Andreas Keil, PhD
  • Phone Number: (352) 392-2439
  • Email: akeil@ufl.edu

Study Locations

  • United States
    • Florida
      • Gainesville, Florida, United States, 32611-2250
        • University of Florida Brain, Cognition and Development Laboratory

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

5 months to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Infants will be included if they are typically developing and between 5.5 and 12.5 months of age, as well as their caregiver.
  • Parents 18-65 years old

Exclusion Criteria:

  1. Infants who were born more that 14 days premature.
  2. Infants who with a history of neurological or visual deficits.
  3. Infants with a history of seizures or a disorder that includes risk of seizures.
  4. Infants with a parent that has a history of seizures of a disorder that includes risk of seizures.
  5. Parents with a history of seizures or a disorder that includes risk of seizures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: 6 month olds
6-month old infants and a parent completed shared book reading and infant visual attention, joint visual attention (dyad, co-occurrence of parent and infant attention toward the book), infant EEG power, and infant-parent EEG coherence were measured in for objects labeled with individual level names, category-level names, and no label. All infant-parent dyads completed all three conditions.
Behavioral: Effects of shared book reading: Labels
Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
Active Comparator: 9 month olds
9-month old infants and a parent completed shared book reading and infant visual attention, joint visual attention (dyad, co-occurrence of parent and infant attention toward the book), infant EEG power, and infant-parent EEG coherence were measured in for objects labeled with individual level names, category-level names, and no label. All infant-parent dyads completed all three conditions.
Behavioral: Effects of shared book reading: Labels
Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
Active Comparator: 12 month olds
12-month old infants and a parent completed shared book reading and infant visual attention, joint visual attention (dyad, co-occurrence of parent and infant attention toward the book), infant EEG power, and infant-parent EEG coherence were measured in for objects labeled with individual level names, category-level names, and no label. All infant-parent dyads completed all three conditions.
Behavioral: Effects of shared book reading: Labels
Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
Active Comparator: Adult Parents
Adult parents of infant participants completed shared book reading with their infants. Joint attention and EEG synchrony data were recorded and combined with infant data for analyses. No adult data were analyzed separately from infant data.
Behavioral: Effects of shared book reading: Labels
Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Infant Visual Attention
Time Frame: Day 1
Infant visual attention was measured for all 3 conditions using head mounted eye-tracking. Duration of visual attention (total duration of infant visual fixations greater than 100 ms each, to the book during shared book reading) was measured within a spatial window of the scene. Proportations of visual attention to the book were calculated by dividing attention duration to the book by the total task duration
Day 1
Infant EEG Steady-state Evoked Potential Frequency Tagging Power
Time Frame: On Day 2
To examine the extent to which infant EEG power, as measured by the signal-to-noise ratio (SNR) was modulated by label condition and age, data were extracted from a mid-occipital cluster of Oz and its 6 nearest neighbors (channels 70, 71, 74, 75, 76, 82, 83) for each of the conditions by age group.
On Day 2

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Infant and Parent EEG Synchrony
Time Frame: On Day 2
Infant and parent EEG synchrony (as a dyad) was quantified and compared across conditions. We used a phase-locking index to quantify EEG dyadic synchrony across conditions. The phase-locking index measures the extent to which the parent and infant oscillatory response is in the same phase across time. This index is bounded between 0 and 1, with 1 being perfect synchrony.
On Day 2
Parent-Infant Visual Joint Attention
Time Frame: On Day 1
Parent and infant visual attention (as a dyad) was measured across conditions using dual parent and infant head mounted eye-tracking. Duration of joint attention (periods of overlap of parent and infant visual fixations to the book during shared book reading) was measured within a spatial window of the scene. Proportions of joint attention were calculated by dividing joint attention duration by the total task duration.
On Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Florida

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Lisa Scott, University of Florida
  • Principal Investigator: Andreas Keil, PhD, University of Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 8, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 14, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 14, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 2, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 3, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 7, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 14, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB202000756-N
  • 1R21HD102715-01 (U.S. NIH Grant/Contract)
  • 5R21HD102715-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Individual, Category, and No-label Conditions

Clinical Trials on Effects of shared book reading: Labels

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings